Skip to main content

Clopidogrel in infants with systemic-to-pulmonary-artery shunts.

Publication ,  Journal Article
Wessel, DL; Berger, F; Li, JS; Dähnert, I; Rakhit, A; Fontecave, S; Newburger, JW; CLARINET Investigators
Published in: N Engl J Med
June 20, 2013

BACKGROUND: Infants with cyanotic congenital heart disease palliated with placement of a systemic-to-pulmonary-artery shunt are at risk for shunt thrombosis and death. We investigated whether the addition of clopidogrel to conventional therapy reduces mortality from any cause and morbidity related to the shunt. METHODS: In a multicenter, double-blind, event-driven trial, we randomly assigned infants 92 days of age or younger with cyanotic congenital heart disease and a systemic-to-pulmonary-artery shunt to receive clopidogrel at a dose of 0.2 mg per kilogram of body weight per day (467 infants) or placebo (439 infants), in addition to conventional therapy (including aspirin in 87.9% of infants). The primary efficacy end point was a composite of death or heart transplantation, shunt thrombosis, or performance of a cardiac procedure due to an event considered to be thrombotic in nature before 120 days of age. RESULTS: The rate of the composite primary end point did not differ significantly between the clopidogrel group (19.1%) and the placebo group (20.5%) (absolute risk difference, 1.4 percentage points; relative risk reduction with clopidogrel, 11.1%; 95% confidence interval, -19.2 to 33.6; P=0.43), nor did the rates of the three components of the composite primary end point. There was no significant benefit of clopidogrel treatment in any subgroup, including subgroups defined by shunt type. Clopidogrel recipients and placebo recipients had similar rates of overall bleeding (18.8% and 20.2%, respectively) and severe bleeding (4.1% and 3.4%, respectively). CONCLUSIONS: Clopidogrel therapy in infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary-artery shunt, most of whom received concomitant aspirin therapy, did not reduce either mortality from any cause or shunt-related morbidity. (Funded by Sanofi-Aventis and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00396877.).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

June 20, 2013

Volume

368

Issue

25

Start / End Page

2377 / 2384

Location

United States

Related Subject Headings

  • Ticlopidine
  • Thrombosis
  • Pulmonary Artery
  • Platelet Aggregation Inhibitors
  • Male
  • Kaplan-Meier Estimate
  • Infant, Newborn
  • Infant
  • Humans
  • Hemorrhage
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wessel, D. L., Berger, F., Li, J. S., Dähnert, I., Rakhit, A., Fontecave, S., … CLARINET Investigators, . (2013). Clopidogrel in infants with systemic-to-pulmonary-artery shunts. N Engl J Med, 368(25), 2377–2384. https://doi.org/10.1056/NEJMoa1114588
Wessel, David L., Felix Berger, Jennifer S. Li, Ingo Dähnert, Amit Rakhit, Sylvie Fontecave, Jane W. Newburger, and Jane W. CLARINET Investigators. “Clopidogrel in infants with systemic-to-pulmonary-artery shunts.N Engl J Med 368, no. 25 (June 20, 2013): 2377–84. https://doi.org/10.1056/NEJMoa1114588.
Wessel DL, Berger F, Li JS, Dähnert I, Rakhit A, Fontecave S, et al. Clopidogrel in infants with systemic-to-pulmonary-artery shunts. N Engl J Med. 2013 Jun 20;368(25):2377–84.
Wessel, David L., et al. “Clopidogrel in infants with systemic-to-pulmonary-artery shunts.N Engl J Med, vol. 368, no. 25, June 2013, pp. 2377–84. Pubmed, doi:10.1056/NEJMoa1114588.
Wessel DL, Berger F, Li JS, Dähnert I, Rakhit A, Fontecave S, Newburger JW, CLARINET Investigators. Clopidogrel in infants with systemic-to-pulmonary-artery shunts. N Engl J Med. 2013 Jun 20;368(25):2377–2384.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

June 20, 2013

Volume

368

Issue

25

Start / End Page

2377 / 2384

Location

United States

Related Subject Headings

  • Ticlopidine
  • Thrombosis
  • Pulmonary Artery
  • Platelet Aggregation Inhibitors
  • Male
  • Kaplan-Meier Estimate
  • Infant, Newborn
  • Infant
  • Humans
  • Hemorrhage